Micro8 is a tool to help patients and their care teams work together on their Hemophilia management plan.

Q: How can Micro8 help your patients with Hemophilia A stay on track with their infusion schedule?

A: Patients and/or caregivers have the flexibility to be reminded of upcoming prophylaxis infusions and to keep track of their progress the way they want to — at home or on the go!

Specifically, patients can
Receive infusion reminders via text message, email, or the Micro8 mobile app
Log infusions or information about bleeds using text messages or the mobile app
Share logs with their healthcare team by sending an e-mail from the mobile app, or online at Micro8.org

Q: How do I keep up-to-date with my patients' progress?

A: When your patients choose to share their information with you, Micro8 allows you to:

View infusion history
Patient activity reports show infusions scheduled, infusions logged, and infusions reported as skipped
View bleed rates
Including patient-reported severity, location of bleeds and uploaded photos of bleeds
Opt to receive notifications
Notifications can include when patients are not logging their scheduled infusions

Q: Is it easy to sign up?

A: Signing up for Micro8 is simple for both patients and healthcare professionals. To sign up, go to Micro8.org and click sign up.

  • Patients can also download the free app for their mobile device at
    • Get it on The App Store
    • Get it on Google Play

    App Store is a service mark; iPhone is a registered trademark of Apple Inc. Android and Google Play are trademarks of Google Inc.

Q: What does Micro8 do with my private information?

A: Nothing!

Micro8 is brought to you by Bioverativ, the company behind ELOCTATE, in partnership with MicroHealth — an innovative community exclusively for people with Hemophilia. Bioverativ does not have access to any user's information. Click here to view the Micro8 privacy policy.

Indications: ELOCTATE [Antihemophilic factor (recombinant), Fc fusion protein] is a recombinant DNA derived, antihemophilic factor indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for: on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

Limitation of Use
ELOCTATE is not indicated for the treatment of von Willebrand disease.

Contraindications: ELOCTATE is contraindicated in patients who have had life-threatening hypersensitivity reactions to ELOCTATE or its excipients.

Warnings and Precautions: Hypersensitivity reactions have been reported with ELOCTATE. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with Factor VIII replacement products. Immediately discontinue ELOCTATE and initiate appropriate treatment if hypersensitivity reactions occur. Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ELOCTATE, including in previously untreated patients. Patients using ELOCTATE should be monitored for the development of Factor VIII inhibitors. Clotting assays (e.g., one-stage) may be used to confirm that adequate Factor VIII levels have been achieved and maintained.

Adverse Reactions: The most frequently occurring adverse reactions (>0.5% of subjects) in clinical trials were arthralgia, malaise, myalgia, headache, and rash.

Please see Full Prescribing Information.